[Treatment of high blood cholesterol in patients with coronary heart disease].
Nagai
Y
Y
Department of Internal Medicine, Izumisano City Hospital.
Yanagi
K
K
Yamashita
S
S
Takemura
K
K
Matsuzawa
Y
Y
D000837:Anion Exchange Resins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001629:Bezafibrate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009525:Niacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011341:Probucol / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D012307:Risk Factors
D000837:Anion Exchange Resins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D009525:Niacin; D011341:Probucol; D001629:Bezafibrate